OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	256
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	231
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	173
Contents page	168
Tubulin targeting agents and their implications in non-cancer disease management	138
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	135
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	135
CIPDB: A biological structure databank for studying cation and π interactions	134
The potential value of 5-androstenediol in countering acute radiation syndrome	120
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	120
The recent progress of deep-learning-based in silico prediction of drug combination	118
Next-generation lung-cancer-on-a-chip: Toward personalized therapy, AI, and CRISPR-driven models	112
Models and approaches to comprehend and address glial inflammation following spinal cord injury	109
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	102
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	101
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	101
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	97
Artificial-intelligence-guided autophagy modulation and nanomedicine design for precision photodynamic cancer therapy	95
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction	94
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	93
Antibody–drug conjugates: What drives their progress?	91
Accelerating the orphan GPCR pipeline: GPR149 as a case study in dual-domain target validation	89
General aspects of powder rheology applied to pharmaceutical formulations	87
Computational modeling approaches and regulatory pathways for drug combinations	86
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	80

Gastroretentive drug delivery systems: A holy grail in oral delivery	79
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	76
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	76
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	73
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	72
MRI assessment of cerebral perfusion in clinical trials	72
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	71
The evolution of ethical and legal regulations of drug research	69
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?	69
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	69
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	68
Global landscape and translational trajectories of flavonoid-based wound-healing research	68
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	68
Engineering virus-like particles for lymph-node targeted cancer immunotherapy: strategies, challenges, and future prospects	67
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	66
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	66
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	66
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	66
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	65
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	65
Organoids in drug development: from predictive models to regulatory integration	65
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	65
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	64
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	63
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	63
Caught between a ROCK and a hard place: current challenges in structure-based drug design	62
Recent advances towards overcoming the blood–brain barrier	62
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	62
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	61
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	60
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	59
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	58
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	58